Triple-negative breast cancer (TNBC) poses a significant challenge in terms of prognosis
and disease recurrence. The limited treatment options and the development of resistance to …

Triple negative breast cancer (TNBC) is a highly heterogeneous disease with a poor
prognosis and a paucity of therapeutic options. In recent years, immunotherapy has …

Simple Summary Triple-negative breast cancer has been historically considered an orphan
disease in terms of therapeutic options. To date, chemotherapy is still the mainstay of …

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with a
poor prognosis. Despite conventional treatments, including surgery, radiation, and …

Breast cancer is a commonly diagnosed female cancer in the world. Triple-negative breast
cancer (TNBC) is the most dangerous and biologically aggressive subtype in breast cancer …

Purpose Immune checkpoint blockade (ICB) therapy has transformed the treatment of triple-
negative breast cancer (TNBC) in recent years. However, some TNBC patients with high …

Introduction To overcome mechanisms of primary and secondary resistance to the anti-
tumor immune response, novel targets such as ICOS, LAG3, and TIM3 are currently being …

Background Early-stage triple-negative breast cancer (TNBC) displays clinical and
biological diversity. From a biological standpoint, immune infiltration plays a crucial role in …

Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …